CD8A and COVID-19: However, a different study examining responses to COVID-19 mRNA vaccines in rituximab-treated patients showed that the expansion of antigen-specific CD8+ T cells was not impaired, but rather the CD8+ T cells were more activated and expressed more effector molecules (63).